Medilink East Midlands Business Awards

19 June 2012

Innovation Day 2012, Thursday 17th May, The Belfry Hotel, Nottingham

As sponsors of the Innovation Award, Helen Johnstone, Partner at Potter Clarkson LLP attended the event and was pleased to see Nottingham-based Novozymes Biopharma walk away with the Award in this year's Medilink East Midlands business competition.

Dave Mead, Business Development Director collected the prize on behalf of the company at the awards evening at the Belfry Hotel, Nottingham.

Dave Mead said: "Novozymes is proud to have won the Medilink Innovation Award. The albumin-based technology is adaptable and can be used for both genetic fusion (Albufuse® Flex) or conjugation (Recombumin® Flex), providing a unique ability to tune the half-life extension of a drug. For our science to be recognised as the most innovative technology of the year, is a real testament to its potential benefit to the market."

Helen Johnstone, said: "The Judges were looking for something revolutionary, which they found in Novozymes' tunable half-life extension technology. The technology allows drug manufacturers more flexibility and control of their drug design, which will lead to more effective drugs at smaller doses, improved quality of life for patients and reduced healthcare costs."

Novozymes Biopharma, develops and manufactures products and technologies that allow pharmaceutical manufacturers to develop innovative, safe, and more effective healthcare products. They won the Innovation Award for their tunable drug half-life extension technology which will allow significant reductions in the frequency of drug administration for patients, making the drugs more effective and less toxic. Novozymes Biopharma also walked away with the Outstanding Achievement award on the night.

In addition to Novozymes Biopharma, four companies won Medilink awards in this year's competition; they are Advancis Medical for Export Achievement; ViVOSmart Medical Devices Ltd for Partnership with the NHS, and XenoGesis Limited for Best Start Up, further evidence of the East Midlands' impact and influence in the healthcare and bioscience business sector. The creativity and innovation shown by these companies has increased jobs, profits and business growth which should contribute to the region's continued climb out of recession. They are also playing a major part in improving patient care, especially in the community, resulting in the cost-effective delivery of healthcare services.

The Awards ceremony was supported through the Healthcare and Bioscience iNet programme, which is part-financed by the European Regional Development Fund (ERDF), and took place on the evening following Medilink's Innovation Day, a conference for the region's leading businesses and academics in the sector.

Speaking after the awards were announced, Dr Darren Clark, Chief Executive of Medilink East Midlands commented: "The innovation that won Novozymes Biopharma this award could be the solution to the problem of poor patient adherence to prescribed medication. It's a problem that costs the US health system an estimated $290 billion in avoidable spending every year, so we're delighted to recognise Novozymes Biopharma's hugely important innovation in this area."

Novozymes Biopharma is automatically entered into the Medilink UK national awards which will take place in early 2013.


People tagged in this article:

Back to all news